- The report contains detailed information about Dendreon Corp. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Dendreon Corp.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Dendreon Corp. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Dendreon Corp. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Dendreon Corp. business.
About Dendreon Corp.
Dendreon Corporation, a biotechnology company, engages in the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients. The companys product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers.
The company's product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed three Phase 3 trials for the treatment of metastatic, castrate-resistant (also known as androgen-independent or hormone-refractory) prostate cancer. Provenge, targets the prostate cancer antigen, prostatic acid phosphatase (PAP), an antigen that is expressed in approximately 90 percent of all prostate cancers.
Product Candidates in Research and Development
Active Immunotherapies and Immunotherapy Targets
lapuleucel-T: Lapuleucel-T is the companys investigational active immunotherapy for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu. Results from a Phase 1 study showed that treatment with lapuleucel-T stimulated significant immune responses in patients with metastatic HER2/neu positive breast cancer, which were shown to be enhanced various booster infusions. The company intents to continue development of an active cellular immunotherapy directed against HER2/neu, including the anticipated initiation of a trial for the treatment of bladder cancer. It is using its Antigen Delivery Cassette technology to develop active immunotherapy product candidates targeted to antigens other than PAP and HER2/neu.
Carbonic AnhydraseIX (CA-9): The company in-licensed the CA-9 antigen from Bayer Corporation, Business Group Diagnostics. Over 75% of primary and metastatic renal cell carcinomas highly express the transmembrane protein CA-9, whereas expression of CA-9 in normal kidney is low or undetectable. CA-9 is also expressed in other cancers, such as non-small cell long and breast tumors and not in the corresponding normal tissue. The company is investigating the use of active immunotherapy product candidates targeted at CA-9.
Carcinoembryonic Antigen (CEA): The company is in-licensed CEA from Bayer Corporation, Business Group Diagnostics.
TRPM8: In 2009, the company commenced its Phase 1 clinical trial to evaluate TRPM8 and the trial is ongoing.
The company has a supply agreement with Diosynth RTP, Inc. covering the commercial production of the antigen used in connection with Provenge.
Dendreon Corporation was founded in 1992.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. DENDREON CORP. COMPANY PROFILE
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. DENDREON CORP. BUSINESS OVERVIEW
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. DENDREON CORP. SWOT ANALYSIS
4. DENDREON CORP. FINANCIAL ANALYSIS
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. DENDREON CORP. COMPETITORS AND INDUSTRY ANALYSIS
5.1. Dendreon Corp. Direct Competitors
5.2. Comparison of Dendreon Corp. and Direct Competitors Financial Ratios
5.3. Comparison of Dendreon Corp. and Direct Competitors Stock Charts
5.4. Dendreon Corp. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Dendreon Corp. Industry Position Analysis
6. DENDREON CORP. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. DENDREON CORP. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. DENDREON CORP. ENHANCED SWOT ANALYSIS2
9. UNITED STATES PESTEL ANALYSIS2
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. DENDREON CORP. IFE, EFE, IE MATRICES2
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. DENDREON CORP. PORTER FIVE FORCES ANALYSIS2
12. DENDREON CORP. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Dendreon Corp. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Dendreon Corp. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Dendreon Corp. Major Shareholders
Dendreon Corp. History
Dendreon Corp. Products
Revenues by Segment
Revenues by Region
Dendreon Corp. Offices and Representations
Dendreon Corp. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Dendreon Corp. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Dendreon Corp. Capital Market Snapshot
Dendreon Corp. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Dendreon Corp. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Dendreon Corp. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Dendreon Corp. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Dendreon Corp. 1-year Stock Charts
Dendreon Corp. 5-year Stock Charts
Dendreon Corp. vs. Main Indexes 1-year Stock Chart
Dendreon Corp. vs. Direct Competitors 1-year Stock Charts
Dendreon Corp. Article Density Chart
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Key Factors Examined by PESTEL Analysis:
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
Porter Five Forces Analysis
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
- Costly to imitate?
- Organized properly?